EGRIFTA SV™ is a stabilized synthetic analogue of growth hormone releasing hormone (GHRH)
EGRIFTA SV™ is an FDA approved treatment* indicated for the reduction of HARD BELLY (excess visceral abdominal fat) in HIV-infected adult patients with lipodystrophy.
EGRIFTA SV™ specifically targets HARD BELLY.

Mechanism of Action

Overview of the GH/IGF-1 axis1

*An approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.

Growth hormone is not approved for the treatment of excess abdominal fat in patients with HIV with lipodystrophy.

References: 1. Longo DL, Fauci AS, Kasper DL, et al. Endocrinology and metabolism. In: Longo DL, Fauci AS, Kasper DL, et al., eds. Harrison’s Principles of Internal Medicine, Volume II. 18th ed. New York, NY: McGraw Hill Companies, Inc.; 2012:2890-2891. 2. Nam SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev. 2000;1(2):73-86. 3. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158.